Cees Noordam

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2267726/publications.pdf

Version: 2024-02-01

70 papers	2,918 citations	172207 29 h-index	182168 51 g-index
73 all docs	73 docs citations	73 times ranked	3460 citing authors

#	Article	IF	Citations
1	Growth, Endocrine Features, and Growth Hormone Treatment in Noonan Syndrome. Journal of Clinical Medicine, 2022, 11, 2034.	1.0	13
2	Praderâ€“Willi Syndrome and Hypogonadism: A Review Article. International Journal of Molecular Sciences, 2021, 22, 2705.	1.8	29
3	Gonadal Hormone Substitution in People with Prader-Labhart-Willi Syndrome: An International Prader-Willi Syndrome Organisation Survey. Hormone Research in Paediatrics, 2021, 94, 176-185.	0.8	2
4	First-year growth in children with Noonan syndrome: Associated with feeding problems?. , 2018, 176, 951-958.		10
5	Ocular findings in Noonan syndrome: a retrospective cohort study of 105 patients. European Journal of Pediatrics, 2018, 177, 1293-1298.	1.3	24
6	Home to Hospital Live Streaming With Virtual Reality Goggles: A Qualitative Study Exploring the Experiences of Hospitalized Children. JMIR Pediatrics and Parenting, 2018, 1, e10.	0.8	7
7	Motor performance in children with Noonan syndrome. American Journal of Medical Genetics, Part A, 2017, 173, 2335-2345.	0.7	5
8	Variable phenotypic expression in a large Noonan syndrome family segregating a novel SOS1 mutation. American Journal of Medical Genetics, Part A, 2017, 173, 2968-2972.	0.7	8
9	Sugarsquare, a Web-Based Patient Portal for Parents of a Child With Type 1 Diabetes: Multicenter Randomized Controlled Feasibility Trial. Journal of Medical Internet Research, 2017, 19, e287.	2.1	22
10	Perceived motor problems in daily life: Focus group interviews with people with Noonan syndrome and their relatives. American Journal of Medical Genetics, Part A, 2016, 170, 2349-2356.	0.7	9
11	A delayed diagnosis of saltâ€wasting congenital adrenal hyperplasia. Clinical Endocrinology, 2016, 85, 497-499.	1.2	2
12	Assessment of psychosocial problems in children with type 1 diabetes and their families: the added value of using standardised questionnaires in addition to clinical estimations of nurses and paediatricians. Journal of Clinical Nursing, 2015, 24, 2143-2151.	1.4	24
13	Parents' experiences, needs, and preferences in pediatric diabetes care: Suggestions for improvement of care and the possible role of the Internet. A qualitative study. Journal for Specialists in Pediatric Nursing, 2015, 20, 218-229.	0.6	14
14	Metabolic Health in Short Children Born Small for Gestational Age Treated With Growth Hormone and Gonadotropin-Releasing Hormone Analog: Results of a Randomized, Dose-Response Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3725-3734.	1.8	22
15	New insights into factors influencing adult height in short SGA children: Results of a large multicentre growth hormone trial. Clinical Endocrinology, 2015, 82, 854-861.	1.2	31
16	The Sugarsquare study: protocol of a multicenter randomized controlled trial concerning a web-based patient portal for parents of a child with type 1 diabetes. BMC Pediatrics, 2014, 14, 24.	0.7	14
17	Teaming up: feasibility of an online treatment environment for adolescents with type 1 diabetes. Pediatric Diabetes, 2014, 15, 394-402.	1.2	29
18	Copy number variants in patients with short stature. European Journal of Human Genetics, 2014, 22, 602-609.	1.4	60

#	Article	IF	Citations
19	Noonan Syndrome: Comparing Mutation-Positive with Mutation-Negative Dutch Patients. Molecular Syndromology, 2013, 4, 227-234.	0.3	19
20	Adult Height in Short Children Born SGA Treated with Growth Hormone and Gonadotropin Releasing Hormone Analog: Results of a Randomized, Dose-Response GH Trial. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4096-4105.	1.8	69
21	Genetic Analysis of Short Children with Apparent Growth Hormone Insensitivity. Hormone Research in Paediatrics, 2012, 77, 320-333.	0.8	45
22	GATA6 haploinsufficiency causes pancreatic agenesis in humans. Nature Genetics, 2012, 44, 20-22.	9.4	249
23	Normal height and weight in a series of ambulant Duchenne muscular dystrophy patients using the 10day on/10day off prednisone regimen. Neuromuscular Disorders, 2012, 22, 500-504.	0.3	7
24	The severe short stature in two siblings with a heterozygous IGF1 mutation is not caused by a dominant negative effect of the putative truncated protein. Growth Hormone and IGF Research, 2011, 21, 44-50.	0.5	8
25	Exercise training improves physical fitness and vascular function in children with type 1 diabetes. Diabetes, Obesity and Metabolism, 2011, 13, 382-384.	2.2	50
26	Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway. European Journal of Human Genetics, 2011, 19, 138-144.	1.4	42
27	Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. European Journal of Human Genetics, 2011, 19, 870-874.	1.4	141
28	Noonan syndrome, the SOS1 gene and embryonal rhabdomyosarcoma. Genes Chromosomes and Cancer, 2010, 49, 635-641.	1.5	33
29	Successful treatment of severe subcutaneous insulin resistance with inhaled insulin therapy. Pediatric Diabetes, 2010, 11, 380-382.	1.2	8
30	Short Stature Associated with a Novel Heterozygous Mutation in theInsulin-Like Growth Factor 1Gene. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E363-E367.	1.8	54
31	Biosimilars: controversies as illustrated by rhGH. Current Medical Research and Opinion, 2010, 26, 1219-1229.	0.9	30
32	Growth in Noonan Syndrome. Hormone Research, 2009, 72, 31-35.	1.8	25
33	Growth Hormone and the Heart in Noonan Syndrome. Hormone Research, 2009, 72, 49-51.	1.8	13
34	InactivatingPAPSS2Mutations in a Patient with Premature Pubarche. New England Journal of Medicine, 2009, 360, 2310-2318.	13.9	139
35	Decreased bone density and treatment in patients with autosomal recessive cutis laxa. Acta Paediatrica, International Journal of Paediatrics, 2009, 98, 490-494.	0.7	13
36	Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births. Diabetologia, 2009, 52, 1683-1685.	2.9	120

#	Article	IF	Citations
37	Reduced levels of GH during GnRH analogue treatment in pubertal short girls born small for gestational age (SGA). Clinical Endocrinology, 2009, 70, 914-919.	1.2	5
38	Growth hormone producing prolactinoma in juvenile cystinosis: a simple coincidence?. Pediatric Nephrology, 2008, 23, 307-310.	0.9	4
39	Are ECG abnormalities in Noonan syndrome characteristic for the syndrome?. European Journal of Pediatrics, 2008, 167, 1363-1367.	1.3	34
40	Denysâ€“Drash syndrome and congenital diaphragmatic hernia: Another case with the 1097Gâ€‰>â€‰A(Arg366His) mutation. American Journal of Medical Genetics, Part A, 2008, 146A, 496-499.	0.7	37
41	Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabetic Medicine, 2008, 25, 277-281.	1.2	106
42	Spinal Stenosis with Paraparesis in Albright Hereditary Osteodystrophy. Pediatric Neurosurgery, 2008, 44, 337-340.	0.4	6
43	Response to Growth Hormone Treatment and Final Height in Noonan Syndrome in a Large Cohort of Patients in the KIGS Database. Journal of Pediatric Endocrinology and Metabolism, 2008, 21, 267-73.	0.4	54
44	Impaired Sertoli Cell Function in Males Diagnosed with Noonan Syndrome. Journal of Pediatric Endocrinology and Metabolism, 2008, 21, 1079-84.	0.4	39
45	Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. European Journal of Endocrinology, 2008, 159, 113-120.	1.9	55
46	Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. European Journal of Endocrinology, 2008, 159, 203-208.	1.9	81
47	Klinefelterâ€™s Syndrome and Prader-Willi Syndrome: A Rare Combination. Psychopathology, 2007, 40, 356-360.	1.1	6
48	Expanding the Genetic Spectrum of Noonan Syndrome. Hormone Research in Paediatrics, 2007, 68, 24-27.	0.8	10
49	Hepatocyte nuclear factor-1 beta mutations cause neonatal diabetes and intrauterine growth retardation: support for a critical role of HNF-1? in human pancreatic development. Diabetic Medicine, 2006, 23, 1301-1306.	1.2	142
50	Absence of Increased Height Velocity in the First Year of Life in Untreated Children with Simple Virilizing Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1205-1209.	1.8	36
51	High Serum Levels of Growth Hormone (GH) and Insulin-Like Growth Factor-I (IGF-I) during High-Dose GH Treatment in Short Children Born Small for Gestational Age. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1390-1396.	1.8	42
52	Treatment of tall stature in boys with somatostatin analogue 201â€“995: effect on final height. European Journal of Endocrinology, 2006, 154, 253-257.	1.9	18
53	Genotypic and phenotypic characterization of Noonan syndrome: New data and review of the literature. American Journal of Medical Genetics, Part A, 2005, 134A, 165-170.	0.7	101
54	Congenital Isolated Adrenocorticotropin Deficiency: An Underestimated Cause of Neonatal Death, Explained byTPITGene Mutations. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1323-1331.	1.8	116

#	Article	IF	Citations
55	From Bone Biology to Bone Analysis. Hormone Research, 2004, 61, 257-269.	1.8	60
56	Genetics and Variation in Phenotype in Noonan Syndrome. Hormone Research in Paediatrics, 2004, 62, 56-59.	0.8	26
57	Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature. European Journal of Pediatrics, 2003, 162, 776-780.	1.3	15
58	Insights Into the Biochemical and Genetic Basis of Glucokinase Activation From Naturally Occurring Hypoglycemia Mutations. Diabetes, 2003, 52, 2433-2440.	0.3	150
59	Bone Mineral Density and Body Composition in Noonan's Syndrome: Effects of Growth Hormone Treatment. Journal of Pediatric Endocrinology and Metabolism, 2002, 15, 81-7.	0.4	10
60	An Adolescent with Food-Dependent Cushing's Syndrome Secondary to Ectopic Expression of GIP Receptor in Unilateral Adrenal Adenoma. Journal of Pediatric Endocrinology and Metabolism, 2002, 15, 853-60.	0.4	13
61	Measuring Skeletal Changes with Calcaneal Ultrasound Imaging in Healthy Children and Adults: The Influence of Size and Location of the Region of Interest. Osteoporosis International, 2001, 12, 970-979.	1.3	15
62	Growth hormone (GH) secretion in children with Noonan syndrome: frequently abnormal without consequences for growth or response to GH treatment. Clinical Endocrinology, 2001, 54, 53-59.	1.2	50
63	Growth hormone treatment in children with Noonanâ€™s syndrome: four year results of a partly controlled trial. Acta Paediatrica, International Journal of Paediatrics, 2001, 90, 889-894.	0.7	8
64	Effects of Growth Hormone Treatment on Left Ventricular Dimensions in Children with Noonanâ€™s Syndrome. Hormone Research in Paediatrics, 2001, 56, 110-113.	0.8	26
65	Newborn Screening for Congenital Adrenal Hyperplasia inthe Netherlands. Pediatrics, 2001, 108, 1320-1324.	1.0	78
66	Can GnRH Agonist Treatment Cause Slipped Capital Femoral Epiphysis?. Journal of Pediatric Endocrinology and Metabolism, 2001, 14, 729-34.	0.4	15
67	Growth hormone treatment in children with Noonan's syndrome: four year results of a partly controlled trial. Acta Paediatrica, International Journal of Paediatrics, 2001, 90, 889-94.	0.7	7
68	Calcaneal Ultrasound Imaging in Healthy Children and Adolescents: Relation of the Ultrasound Parameters BUA and SOS to Age, Body Weight, Height, Foot Dimensions and Pubertal Stage. Osteoporosis International, 2000, 11, 967-976.	1.3	67
69	I-Cell Disease Presenting with Severe Hypophosphatemia and Cardiomyopathy. Neuropediatrics, 2000, 31, 49-50.	0.3	5
70	Growth before and during Growth Hormone Treatment in Children Operated for Craniopharyngioma. Hormone Research, 1997, 48, 258-262.	1.8	17